Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

10 Customer Reviews

  • Chromosomal single-strand break repair rates in the indicated RPE-1 cell lines following treatment with 50 μM H2O2 in the presence/absence of 10 μM of the PARP inhibitor (PARPi) Veliparib, as measured by alkaline comet assay. Data are the mean tail moment of 100 cells per sample per experiment and are the average (-/+SEM) of three independent experiments. Two-way ANOVA analysis between relevant genotypes is presented (ns= not significant, **= p<0.01, ***= p<0.001).

    Nature, 2017, 541(7635):87-91. Veliparib (ABT-888) purchased from Selleck.

    (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  • OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

  • Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

    Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NYS1NmgyU2mwYYPlJGF{e2G7 NGjC[lU{OCCvaX6= NGD0V4xKdmirYnn0bY9vKG:oIGDBVnAyKHerdHigSWM2OCCxZjCwMlAxOiEQvF2= M2X4WVE6QDh6N{[w
Jurkat MWTLbY5ie2ViQYPzZZk> MYi5OkBp MXXEUXNQ NGrobWFKdmirYnn0bY9vKG:oIGDBVnAyKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTD3bZRpKEWFNUCgc4YhOyEQvF2= M{Tn[|I{QDVyMUm5
Capan1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD5SoU4OiCq MnjHSG1UVw>? M4n2XGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRnJESTJiZ3Xu[UBufXSjdHXkJIh2dWGwIFPhdIFvOSClZXzsd{B4cXSqIFnDOVAhd2ZiM{muO{DPxE1? Mkn0NlQ{QTh|OEO=
DT40 MkXVR5l1d3SxeHnjJGF{e2G7 MnvBO|IhcA>? MYfEUXNQ M{HY[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGOqaXPr[Y4hSlKFQUKt[IVncWOrZX70JGRVPDBiY3XscJM> MkX0NlQ6OjJ3OEe=
ML-1 M1;z[mFxd3C2b4TpZ{BCe3OjeR?= Mn;5Nk42KM7:TR?= NIfCc5czPCCq MWjEUXNQ M33tNHN6dmW{Z3nzeIlk[WyueTDlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDNUE0yKGOnbHzz NH\aSWEzPDh7NUGzOS=>
HCT-116 MV\LbY5ie2ViQYPzZZk> M3jtdlAvPSEQvF2= MkfnNlQhcA>? NEPaPW1RSVKSIHHjeIl3cXS7IHTlZ5Jm[XOncx?= M3LyflI{ODV2MkGz
UM-SCC1 Mlr6R5l1d3SxeHnjJGF{e2G7 MVexNEDPxE1? MlTqNlQhcA>? MUTS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= M3\3T|IyQTF{NkKw
FaDu NYrZcWRlS3m2b4TvfIlkKEG|c3H5 NYHHT2NlOTBizszN Mnj0NlQhcA>? M3fYU3Jm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 NH3NPXczOTlzMk[yNC=>
PC-3 NFzoSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDoPG0yOCEQvF2= NIjWWVRKdmS3Y3XzJIEhe2mpbnnmbYNidnRiaX7obYJqfGmxbjDpckBkd2yxbomg[o9zdWG2aX;uxsA> NFO4ZmgzOTV5MUmxNi=>
EoL-1-cell M4\Q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HzS2lEPTB;MT6wO|k5KM7:TR?= MWPTRW5ITVJ?
NCI-SNU-5 M3njXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETrW|VKSzVyPUOuNVI5PDFizszN M{XM[3NCVkeHUh?=
BV-173 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwNEW0NFkh|ryP NF;neZpUSU6JRWK=
HCC1806 NYP5NYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7yWItKSzVyPUWuO|UyPzNizszN MmPzV2FPT0WU
COLO-680 NFfyPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDpeWxKSzVyPU[uNlE1ODZizszN MWjTRW5ITVJ?
HCC2218 NIO2dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HR[WlEPTB;Nz63PVcxPCEQvF2= Mnf5V2FPT0WU
SK-MEL-24 M{WxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPLTZF5UUN3ME23MlgyQTJ2IN88US=> NE\GRm1USU6JRWK=
NCI-H720 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOyTWM2OD16LkSzOlA{KM7:TR?= MoDGV2FPT0WU
KASUMI-1 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRThwOEmyOlYh|ryP Mo\HV2FPT0WU
HAL-01 M4XxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTxTWM2OD17Lki4OlIh|ryP Mkn5V2FPT0WU
CAL-33 NFrkTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFyLkSzOEDPxE1? M2Pme3NCVkeHUh?=
SK-MEL-1 NHXtWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1zMj60OlY{KM7:TR?= MYHTRW5ITVJ?
Ramos-2G6-4C10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7z[4VUUUN3ME2xNk41PzV{IN88US=> MlfjV2FPT0WU
KY821 NYnybFBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXEeoZVUUN3ME2xNk41QDVizszN MoTLV2FPT0WU
HEC-1 NYnxZXMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDPTWM2OD1zMj65NVk3KM7:TR?= MnvlV2FPT0WU
SK-NEP-1 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF|LkG2OkDPxE1? MWXTRW5ITVJ?
MN-60 M{T4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXTTWM2OD1zMz61N|g6KM7:TR?= MlrUV2FPT0WU
DU-145 NEm3RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PHZ2lEPTB;MUOuPVA2OyEQvF2= MmTwV2FPT0WU
EW-3 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPeGlEPTB;MUSuOVU3PSEQvF2= NE\vTZRUSU6JRWK=
OS-RC-2 NHTDboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTjdoJKSzVyPUG1Mlk2QDlizszN NYHoXXVwW0GQR1XS
RPMI-8226 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7MfJJLUUN3ME2xOk4zODR{IN88US=> M4TpbXNCVkeHUh?=
ChaGo-K-1 NHPnPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6TWM2OD1zNj61N|I2KM7:TR?= M1jLXXNCVkeHUh?=
DEL NWDTTmhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TScWlEPTB;MU[uOlcyPyEQvF2= NVT3emlRW0GQR1XS
GP5d MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\XTWM2OD1zNz6wOVMh|ryP MULTRW5ITVJ?
COLO-668 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jzRmlEPTB;MUeuOlI6PCEQvF2= NXzZb2xxW0GQR1XS
H9 NHj2fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF6LkK4N|Mh|ryP MnnrV2FPT0WU
NKM-1 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zJb2lEPTB;MUiuOVEyQSEQvF2= MlriV2FPT0WU
KYSE-150 M{\iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF6Lkm5PFYh|ryP Ml7pV2FPT0WU
Daoy MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXoTWM2OD1zOT61OlQ6KM7:TR?= NHTMbWpUSU6JRWK=
ECC10 NIXhTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJyLke0OVUh|ryP NFezOG5USU6JRWK=
A388 NVn2NGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK3TWM2OD1{MT65NFkyKM7:TR?= NXTqTnRTW0GQR1XS
MHH-NB-11 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHHTWM2OD1{Mz6xN|Y{KM7:TR?= Ml3kV2FPT0WU
HCC1937 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kTWM2OD1{ND63OFYh|ryP NGmwbJdUSU6JRWK=
TGBC11TKB M1fsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjBTWM2OD1{NT62PFY{KM7:TR?= MojVV2FPT0WU
CTV-1 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu1NVVKSzVyPUK1Mlg6PjlizszN NY\2U|FlW0GQR1XS
NCI-H2029 M{L3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\iTWM2OD1{Nj60NlM5KM7:TR?= MoTnV2FPT0WU
HLE MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDKd25KSzVyPUK3MlA2PCEQvF2= NUX0dpptW0GQR1XS
NCI-H1693 M{\6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ5LkK4PVgh|ryP MVXTRW5ITVJ?
HCC70 M3jGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\BN2ZKSzVyPUK3MlczPDZizszN MYfTRW5ITVJ?
BEN NXvWWlY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHvTWM2OD1{Nz65OVY3KM7:TR?= MmDLV2FPT0WU
LB771 NFjqcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmraTWM2OD1{OD64N|c{KM7:TR?= NYHmcnJ2W0GQR1XS
697 NWjjbWlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHtNJFKSzVyPUK5MlAzOzVizszN NXnR[INDW0GQR1XS
LU-139 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[0TWM2OD1{OT6zO|Q5KM7:TR?= M{TS[HNCVkeHUh?=
EW-13 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXoOXdXUUN3ME2yPU4{QDF2IN88US=> MnT6V2FPT0WU
MOLT-13 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHFXZpKSzVyPUK5MlM5OTRizszN NGPFNnVUSU6JRWK=
L-363 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XHcWlEPTB;MkmuOFc6QCEQvF2= M37lVnNCVkeHUh?=
EM-2 NWn5XHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL5cmNKSzVyPUK5MlQ6ODFizszN NYPUNmI4W0GQR1XS
RS4-11 M4Pl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW5d3lOUUN3ME2zNE41OjRzIN88US=> NYXofolzW0GQR1XS
A2780 NUjyTHhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;XT2lEPTB;M{CuO|Q2PyEQvF2= NGHVcohUSU6JRWK=
KU812 M4Swcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSR4RRUUN3ME2zNk4{PjR{IN88US=> M1LiSnNCVkeHUh?=
COLO-684 M{P1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DUZ2lEPTB;M{OuN|U6QSEQvF2= MXzTRW5ITVJ?
MFE-280 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1b2NKSzVyPUOzMlM5QDlizszN NGnmV5ZUSU6JRWK=
KG-1 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN|Lk[wNFEh|ryP NGfuXYVUSU6JRWK=
JVM-3 M3i3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XxXGlEPTB;M{WuOVg3QCEQvF2= MWTTRW5ITVJ?
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lb2lEPTB;M{WuPFQ6QSEQvF2= MWXTRW5ITVJ?
LAMA-84 NHTHRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:4RmlEPTB;M{[uO|M1PSEQvF2= NUPUbox4W0GQR1XS
MOLT-16 NXfHR3JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojPTWM2OD1|Nj65OVIh|ryP Mkf4V2FPT0WU
H4 NHjudWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ySG1VUUN3ME2zO{42PjdizszN NF;6SW5USU6JRWK=
T47D NGjUOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDJdXRlUUN3ME2zO{44ODF6IN88US=> MVvTRW5ITVJ?
CAL-54 M2jY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfXUIVLUUN3ME2zO{46PjZizszN NVzBPYZ4W0GQR1XS
SW982 NXvTelJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTN6LkC5PVgh|ryP NEO0e5FUSU6JRWK=
IGROV-1 NI[zTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN7LkOzNFQh|ryP M4Lt[XNCVkeHUh?=
NB14 NUjzT3M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRyLkewN|Eh|ryP M1H2T3NCVkeHUh?=
HCC1187 M3zufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRzLkK3O|Eh|ryP M{XGRXNCVkeHUh?=
SBC-1 NFLuN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Oe2lEPTB;NEGuN|A3OyEQvF2= MX\TRW5ITVJ?
KARPAS-45 NXHueYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMWGlEPTB;NEGuOFgyQCEQvF2= MYPTRW5ITVJ?
MOLT-4 NEK4VG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTR{LkK1N|gh|ryP NUTTVVRHW0GQR1XS
JVM-2 NYfxNoJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z2SmlEPTB;NEKuPVIxPyEQvF2= MU\TRW5ITVJ?
A4-Fuk MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD12Mz61OlkyKM7:TR?= MnfJV2FPT0WU
MDA-MB-361 NH7x[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjHTWM2OD12Mz64OFE1KM7:TR?= Mln5V2FPT0WU
BALL-1 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrCUmVVUUN3ME20N{46PTN{IN88US=> MV;TRW5ITVJ?
T98G MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PlZWlEPTB;NESuPFUyPyEQvF2= NILvV4tUSU6JRWK=
Mo-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYryeW84UUN3ME20OU43Ozh7IN88US=> Mn63V2FPT0WU
MHH-PREB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fvTmlEPTB;NEWuO|U5PSEQvF2= MYLTRW5ITVJ?
ALL-PO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXOTWM2OD12Nz6zO|kyKM7:TR?= MU\TRW5ITVJ?
NCI-H510A NIe5eZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\qO4dKSzVyPUS3MlkxOzRizszN M361dXNCVkeHUh?=
ML-2 NX\4WHhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n1dWlEPTB;NEmuO|g2PiEQvF2= M3nrXnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03044795 Not yet recruiting Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2018 Phase 2
NCT03044795 Not yet recruiting Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2018 Phase 2
NCT03581292 Recruiting Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma National Cancer Institute (NCI) October 31 2018 Phase 2
NCT03581292 Recruiting Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma National Cancer Institute (NCI) October 31 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID